Conditions: Chronic Lymphocytic Leukemia(CLL) Small Lymphocytic Lymphoma
Keywords: chronic lymphocytic leukemia (CLL) Small Lymphocytic Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL

Hypothesis- lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.

Detailed description:
Treatment response of lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.

Arms:
arm 1: response to combination of azacitidine + lenalidomide A Phase II, Single Arm Study Examining the Combination of Revlimid (Lenalidomide) and Vidaza (Azacitidine) (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Interventions: intervention 1: Revlimid intervention 2: Azacitidine
Intervention descriptions: intervention 1: Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21). intervention 2: Azacitidine 75 mg/m2 IV or SC D 1-5

Protocol document: